ClinicalTrials.gg
Not yet recruitingNCT07208032Updated Oct 6, 2025

Pulsed Radiofrequency in Post Herptic Neuralgia

An interventional study of Irregular Pulsed Radiofrequency (STP) and regular pulsed Radiofrequency in Postherpetic Neuralgia (PHN), sponsored by Sohag University. Not yet recruiting at 2 sites in Egypt. Per ClinicalTrials.gov, last updated 2025-10-06.

Sponsored by Sohag University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies in Neuralgia, Postherpetic with a site in Egypt — 4 open to participants now, 4 under way, none of them phase 3. Neuralgia, Postherpetic · Egypt.

Planned enrollment
2nd of 10
100 · median 56
Started
2025
with 4 others
No phase
9 of 10
4 open now
Registered
7th of 10
by date
Lead sponsor
1 of 10
Sohag University

Among the 10 studies in Neuralgia, Postherpetic with a site in Egypt, this one is the 2nd largest by planned enrollment, is one of 5 that started in 2025, is one of 9 with no phase, and was the 7th registered.

Neuralgia, Postherpetic

197 studies on the registry are indexed under Neuralgia, Postherpetic; 29 are open to participants now.

Browse Neuralgia, Postherpetic studies →

Open to participants now

4 of the 10 studies in Neuralgia, Postherpetic with a site in Egypt are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 18 Neuralgia, Postherpetic studies recruiting now, 8 (44%) set no upper age limit and 5 (28%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Neuralgia, Postherpetic with a site in Egypt, or all of them as a file.
02

Study summary

Comparing between regular pulsed Radiofrequency and irregular pulsed Radiofrequency for treatment of postherpetic neuralgia

03

Conditions studied

  • Postherpetic Neuralgia (PHN)
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients with Herps Zoster neuralgia lasting more than one month Neck thoracic lumbar ganglion involvement to conventional therapy

Exclusion criteria

Exclusion Criteria:

Infection ,tumour at the puncture site Severe cardiovascular or cerebrovascular disease Liver, kidney dysfunction Abnormal coagulation Uncontrolled DM Psychatric diseases Patient refusal

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Irregular pulsed Radiofrequency treatment (STP)

    Procedure: Irregular Pulsed Radiofrequency (STP)

  • Active comparator
    Regular pulsed Radiofrequency treatment

    Procedure: regular pulsed Radiofrequency

Interventions

  • ProcedureIrregular Pulsed Radiofrequency (STP)

    Flouroscopic guided irregular pulsed Radiofrequency (STP) for dorsal root ganglion

  • Procedureregular pulsed Radiofrequency

    Fluoroscopic guided regular pulsed Radiofrequency for the dorsal root ganglion

06

What researchers measure

Primary outcomes

  1. Pain level by Numerical Rating Scale

    Time frame: One day , One week , One month ,Three months postprocedure.

07

Study locations

2 sites
  • Medical research ethics committee
    Sohag, Sohag Governorate 82511, Egypt
  • Medical research ethics committee
    Sohag, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2025; primary completion for Mar 2026, 5 months later.

Of 30 non-industry interventional studies with no phase under Neuralgia, Postherpetic, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 35. This study's planned 5 months is below that.

Counting every sponsor, half of 32 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2025
First posted
Oct 6, 2025
StartEst.
Oct 1, 2025
Primary completionEst.
Mar 31, 2026
CompletionEst.
Mar 31, 2026
Last update
Oct 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07208032
Lead sponsor
Sohag University
Responsible party
Ahmed Mohamed Elhalwagy (Lecturer of anaesthesia and pain management, Sohag University) — Principal investigator
First posted
Oct 6, 2025
Start date
Oct 1, 2025 (estimated)
Primary completion
Mar 31, 2026 (estimated)
Completion
Mar 31, 2026 (estimated)
Last update
Oct 6, 2025

Study contacts

Ahmed Mohamed Elhalwagy
Contact
ahmed.elhalwagy@med.sohag.edu.eg
+201002674242

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion